What kind of company is Epclusa?

Epclusa is a medication used to treat Hepatitis C virus infection. It is a combination of two drugs, sofosbuvir and velpatasvir. The medication was approved by the US Food and Drug Administration (FDA) in 2016 and is produced by Gilead Sciences.

The combination of sofosbuvir and velpatasvir work together to inhibit the replication of the Hepatitis C virus, which is responsible for causing liver damage and can lead to liver cirrhosis and liver cancer if left untreated.

Epclusa is taken orally, usually once a day for 12 weeks. The effectiveness of the medication has been shown to be high, with cure rates of over 90% in patients with Hepatitis C genotypes 1-6.

One of the advantages of Epclusa is that it is a pan-genotypic medication, meaning that it is effective against all genotypes of the Hepatitis C virus, whereas previous treatments were genotype-specific. Another advantage is that it generally has fewer side effects than previous treatments, with the most common side effects being headache, fatigue, and nausea.

The cost of Epclusa was initially high, with a list price of $74,760 for a 12-week treatment course. However, there are now co-pay coupons and other assistance programs available to help patients afford the medication. Additionally, the medication is available for purchase online at a lower cost.

Overall, Epclusa is a highly effective medication with a high cure rate for Hepatitis C infection. Its pan-genotypic nature and low side effect profile make it an important development in the treatment of Hepatitis C.